zomedica corp (NYSE American:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20 The median estimate represents a +358.19% increase from the last price of 0.26.
Should I sell my zomedica stock?
Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding Zomedica Pharmaceuticals Corp is ‘ Strong Sell ‘.
Will ZOM stock ever go up?
There is potential for a short term uptick in the Zom stock price , especially as the active weekly candle is mildly bullish. The relative strength index is relatively oversold and has been for quite some time. A mild divergence also supports the notion of a slight recovery in the Zom stock price in the near term.
Will ZOM recover?
ZOM stock will likely struggle to recover in price over the next few months It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Is Zomedica being shorted?
What is Zomedica’s current short interest? Short interest is the volume of Zomedica shares that have been sold short but have not yet been covered or closed out. As of June 15th, traders have sold 101,490,000 shares of ZOM short. 10.52% of Zomedica’s shares are currently sold short.
Why is Zom dropping?
CEO Robert Cohen said the move was precipitated by ” changes at our current distributor that we believe have impacted its ability to market our products effectively” Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Is Zomedica a real company?
About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Is Zomedica a good long term investment?
Moreover, during the nine months that ended on Sept. 30, 2021, Zomedica reported $52,331 of revenue and a net earnings loss of $15.1 million. Clearly, its current financial performance won’t be sustainable for the long-term.
What does ZOM company do?
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings.
How many Zomedica shares does Vanguard own?
2022-02-14 – Vanguard Group Inc has filed a 13F-HR form disclosing ownership of 41,635,682 shares of Zomedica Pharmaceuticals Corp. (US:ZOM) with total holdings valued at $12,762,000 USD as of 2021-12-31.
Does Zom reverse split?
Despite now generating revenue from the sale of its Truforma diagnostics system, Zomedica is valued at nearly 70 times Wall Street’s projected sales for 2023. It’s also nowhere near profitability. It’s a strong candidate to enact a reverse split sometime over the next 12 to 18 months.
Why did Zomedica stock go up today?
Shares of Zomedica (ZOM -0.25%) were soaring 14.7% higher as of 11:41 a.m. ET on Monday. The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday.
Is Sundial growers a buy?
Following the Q3 earnings report, Sundial shares experienced a strong rally. However, even though SNDL is worth just over 50 cents and is under pressure to pass the $1-per-share level to remain in compliance with Nasdaq, here are three reasons why buying the stock ahead of earnings could be a good deal.